Example logo GIS 26

Global Innovation Summit 2026

6 May 2026 | Basel, Switzerland

Home
Register
Register
Register

Krzysztof Kucharczyk

CEO

BioVectis

Warszawa, Poland

5 profile visits

I have over 20 years of expertise in life sciences, in vitro diagnostics, and medical device development, manufacturing, and commercialization.

My organisation

BioVectis

BioVectis

SME

Warszawa, Poland

BioVectis designs, manufactures and commercializes precision Life‑Science R&D tools and advances complementary therapeutics and diagnostics, leveraging 20+ years of academic collaborations. Select portfolio · Scutum\_IO — neoepitope discovery pipeline to accelerate personalized cancer vaccines. · Appus — natural‑origin preclinical candidate for autoimmune/inflammatory disease with robust safety and efficacy signals (CIA model). · DNAPointer® System — flagship native slab‑gel platform with ±0.1 °C control for protein complexes (-protein, -membrane, -nucleic acids) native high‑resolution separation and preparative recovery; workflows for MS/NGS and cryo‑EM/NMR. · AgePlex™ Kit — five‑CpG epigenetic human biological age assay (~3.4 years MAE) for forensics, wellness and research. · Scutum\_ND — rHVT recombinant vaccine (NDV + Marek’s) with pilot field efficacy >98% and DIVA diagnostics; compatible with in‑ovo automation. · VelaMed — point‑of‑care VOC diagnostic (DMS + ML) with AUC >0.98 for IBD detection; applications in human diagnostics and livestock/food QC. We seek · R&D partners, seed investors, distributors and grant collaborators.
Read more

About me

Over 25 years’ experience in life sciences, in vitro diagnostics, and medical device development, manufacturing and commercialization. I design evidence‑based business strategies to maximize the value of advanced life‑science technologies and have led market and business development for multiple products co‑developed with academic partners. I drive commercial expansion across Poland and the EU, focusing on market analysis, strategic partnerships, sales execution and fundraising to enable implementation. I also invest in life‑sciences startups, applying rigorous, technical due diligence and deep mechanistic analysis to identify high‑probability opportunities. Co‑author of ~30 scientific publications and patents; h‑index 11 with ~900 citations

Social media